分子核医学的发展和应用前景

方圣伟; 奚望; 张宏; 方圣伟; 奚望; 张宏

doi:10.3760/cma.j.issn.1673-4114.2009.06.001

[1]

De Wever W,Coolen J,Verschakelen JA.Integrated PET/CT and cancer imaging.JBR-BTR,2009,92(1):13-19.

[2]

Mittra E,Quon A.Positron emission tomography/computed tomography:the current technology and applications.Radiol Clin North Am,2009,47(1):147-160.

[3]

De Wever W,Stroobants S,Verschakelen JA.Integrated PET/CT in lung cancer imaging:history and technical aspects.JBR-BTR,2007,90(2):112-119.

[4]

Pichler BJ,Judenhofer MS,Pfannenberg C.Multimodal imaging approaches:PET/CT and PET/MRI.Handb Exp Pharmacol,2008,185(Pt 1):109-132.

[5]

Shao Y,Cherry SR,Farahani K,et al.Development of a PET detector system compatible with MKI/NMR systems.IEEE Transact Nucl Sci,1997,44(3):1167-1171.

[6]

Pichler BJ,Judenhofer MS,Catana C,et al.Performance test of an LSO-APD detector in a 7-T MRI scanner for simultaneous PET/MRI.J Nucl Med,2006,47(4):639-647,.

[7]

Catana C,Procissi D,Wu Y,et al.Simultaneous in vivo positron emission tomography and magnetic resonance imaging.Proc Natl Acad Sci USA,2008,105(10):3705-3710.

[8]

Antoch G,Bockisch A.Combined PET/MRI:a new dimension in whole-body oncology imaging?.Eur J Nucl Med Mol Imaging,2009,36(Suppl 1):S113-S120.

[9]

Judenhofer MS,Wehrl HF,Newport DF,et al.Simultaneous PET-MRI:a new approach for functional and morphological imaging.Nat Med,2008,14(4):459-465.

[10]

Pichler BJ,Judenhofer MS,Wehrl HF.PET/MRI hybrid imaging:devices and initial results.Eur Radiol,2008,18(6):1077-1086.

[11]

Seemann MD.Whole-body PET/MRI:the future in oncological imaging.Technol Cancer Res Treat,2005,4(5):577-582.

[12]

Tartis MS,Kruse DE,Zheng H,et al.Dynamic micro PET imaging of ultrasound contrast agents and lipid delivery.J Control Release,2008,131(3):160-166.

[13]

Charnley N,Donaldson S,Price P.Imaging angiogenesis.Methods Mol Biol,2009,467:25-51.

[14]

Dijkgraaf I,Beer AJ,Wester HJ.Application of RGD-containing peptides as imaging probes for alphavbeta3 expression.Front Biosci,2009,14:887-899.

[15]

Huber JS,Moses WW,Pouliot N,et al.Dual-modality PET/ultrasound imaging of the prostate.Nuclear Science Symposium Conference Record,2005 IEEE.2005:2187-2190.

[16]

Choy G,Choyke P,Libutti SK.Current advances in molecular imaging:noninvasive in vivo bioluminescent and fluorescent optical imaging in cancer research.Mol Imaging,2003,2(4):303-312.

[17]

Dothager RS,Flentie K,Moss B,et al.Advances in bioluminescence imaging of live animal models.Curr Opin Biotechnol,2009,20(1):45-53.

[18]

Waerzeggers Y,Klein M,Miletic H,et al.Multimodal imaging of neural progenitor cell fate in rodents.Mol Imaging,2008,7(2):77-91.

[19]

Zhao H,Gao F,Tanikawa Y,et al.Time-resolved diffuse optical tomography and its application to in vitro and in vivo imaging.J Biomed Opt,2007,12(6):062107.

[20]

Alexandrakis G,Rannou FR,Chatziioannou AF.Effect of optical property estimation accuracy on tomographic bioluminescence imaging:simulation of a combined optical-PET (OPET)system.Phys Med Biol,2006,51(8):2045-2053.

[21]

Prout DL,Silverman RW,Chatziioannou A.Detector concept for OPET-A combined PET and optica imaging system.IEEE Trans Nucl Sci,2004,51(3):752-756.

[22]

Alexandrakis G,Rannou FR,Chatziioannou AF.Tomographic bioluminescence imaging by use of a combined optical-PET(OPET) system:a computer simulation feasibility study.Phys Med Biol,2005,50(17):4225-4241.

[23]

Goetz C,Breton E,Choquet P,et al.SPECT low-field MRI system for small-animal imaging.J Nucl Med,2008,49(1):88-93.

[24]

Rufini V,Shulkin B.The evolution in the use of MIBG in more than 25 years of experimental and clinical applications.Q J Nucl Med Mol Imaging,2008,52(4):341-350.

[25]

Lee HY,Li Z,Chen K,et al.PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles.J Nucl Med,2008,49(8):1371-1379.

[26]

Cai W,Chen K.Li ZB,et al. Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature.J Nucl Med,2007,48(11):1862-1870.

[27]

Bhushan KR,Misra P,Liu F,et al.Detection of breast cancer microcalcifications using a dual-modality SPECT/NIR fluorescent probe.J Am Chem Soc,2008,130(52):17648-17649.

[28]

Pene F,Courtine E,Cariou A,et al.Toward theragnostics.Crit Care Med,2009,37(1 Suppl):S50-S58.

[29]

Waerzeggers Y,Monfared P,Viel T,et al.Methods to monitor gene therapy with molecular imaging.Methods,2009,48(2):146-160.

[30]

Medarova Z,Pham W,Farrar C,et al.In vivo imaging of siRNA delivery and silencing in tumors.Nat Med,2007,13(3):372-377.

[31]

Miyagawa T,Gogiberidze G,Serganova I,et al.Imaging of HSV-tk reporter gene expression:comparison between[¹⁸F]FEAU,[¹⁸F]FFEAU,and other imaging probes.J Nucl Med,2008,49(4):637-648.

[32]

Xing L, Deng X,Kotedia K,et al.Non-invasive molecular and functional imaging of cytosine deaminase and uracil phosphoribosyltransferase fused with red fluorescence protein.Acta Oncol,2008,47(7):1211-1220.

[33]

Zhang H,Zheng X,Yang X,et al.¹¹C-NMSP/¹⁸F-FDG microPET to monitor neural stem cell transplantation in a rat model of traumatic brain injury.Eur J Nucl Med Mol Imaging,2008,35(9):1699-1708.

[34]

Zinn KR,Chaudhuri TR.The type 2 human somatostatin receptor as a platform for reporter gene imaging.Eur J Nucl Med Mol Imaging,2002,29(3):388-399.

[35]

Wolny M,Syrenicz A.Sodium iodide symporter in physiology and diseases-the current state of knowledge,Endokrynol Pol,2007,58(6):512-521.

[36]

van Dillen IJ,Mulder IVH,Vaalburg W,et al.Influence of the bystander effect on HSV-tk/GCV gene therapy.A review.Curr Gene Ther,2002,2(3):307-322.

[37]

Jacobs A,Tjuvajev JG,Dubrovin M,et al.Positron emission tomography-based imaging of transgene expression mediated by replication-conditional,oncolytic herpes simplex virus type 1mutant vectors in vivo.Cancer Res,2001,61(7):2983-2995.

[38]

赵春华.干细胞原理、技术与临床应用.北京:化学工业出版社.2006.

[39]

Tjuvajev JG,Stockhammer G,Desai R,et al.Imaging the expression of transfected genes in vivo.Cancer Res,1995,55(24):6126-6132.

[40]

Tjuvajev JG,Avril N,Oku T,et al.Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography.Cancer Res,1998,58(19):4333-4341.

[41]

Yaghoubi SS,Gambhir SS.PET imaging of herpes simplex virus type 1 thymidine kinase(HSV1-tk) or mutant HSV1-sr39tk reporter gene expression in mice and humans using[¹⁸F]FHBG.Nat Protoc,2006,1(6):3069-3075.

[42]

Cao F,Lin S,Xie X,et al.In vivo visualization of embryonic stem cell survival,proliferation,and migration after cardiac delivery.Circulation,2006,113(7):1005-1014.

[43]

Willmann JK,van Bruggen N,Dinkelborg LM,et al.Molecular imaging in drug development.Nat Rev Drug Discov,2008,7(7):591-607.

[44]

Dimasi JA.Risks in new drug development:approval success rates for investigational drugs.Clin Pharmacol Ther,2001,69(5):297-307,.

[45]

Fischman AJ,Alpert NM,Rubin RH.Pharmacokinetic imaging:a noninvasive method for determining drug distribution and action.Clin Pharmacokinet,2002,41(8):581-602.

[46]

Zhu Z,Guo N,Narendran R,et al.The new PET imaging agent[¹¹C] AFE is a selective serotonin transporter ligand with fast brain uptake kinetics.Nucl Med Biol,2004,31(8):983-994.

[47]

Bergstrom M,Westerberg G,Nemeth G,et al.MAO-A inhibition in brain after dosing with esuprone,moclobemide and placebo in healthy volunteers:in vivo studies with positron emission tomography.Eur J Clin Pharmacol,1997,52(2):121-128.

[48]

Czernin J,Phelps ME.Positron emission tomography scanning:current and future applications.Annu Rev Med,2002,53:89-112.

[49]

Blankenberg FG,Backer MV,Levashova Z,et al.In vivo tumor angiogenesis imaging with site-specific labeled (99m)Tc-HVNIC-VEGF.Eur J Nucl Med Mol Imaging,2006,33(7):841-848.

[50]

Beer AJ,Haubner R,Goebel M,et al.Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer ¹⁸F-galacto-RGD in cancer patients.J Nucl Med.2005,46(8):1333-1341.

[51]

Weber WA.Positron emission tomography as an imaging biomarker.J Clin Oncol,2006,24(20):3282-3292.